Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor

American Journal of Health-System Pharmacy

Volumn 69, Issue 10, 2012, Pages 857-861

  James, Christopher ^a   Preininger, Lee ^a   Sweet, Meryn ^b  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antiretroviral agents; Blood levels; Dosage; Drug administration; Drug interactions; HIV infections; Mechanism of action; Metabolism; Pharmacokinetics; Rilpivirine; Toxicity

Indexed keywords

ABACAVIR; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CLARITHROMYCIN; CYTOCHROME P450 3A; EFAVIRENZ; EMTRICITABINE; ERYTHROMYCIN; ETRAVIRINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMIVUDINE; METHADONE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

CREATININE BLOOD LEVEL; DEPRESSION; DIZZINESS; DREAM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MEDICAL LITERATURE; NAUSEA; NIGHTMARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMACH PH; TREATMENT RESPONSE;

EID: 84861469365     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110395     Document Type: Review

References (24)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-60. (Pubitemid 28135961)
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10, 2011. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2011 Sep 1).
3. Food and Drug Administration. Drugs@FDA: label and approval history for rilpivirine. www.access-data. fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist (accessed 2011 Jun 1).
4. Edurant (rilpivirine) package insert. Raritan, NJ: Tibotec Therapeutics; 2011 May.
5. Fletcher CV, Kakuda TN. Human immunodeficiency virus infection. In: DePiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiological approach. 6th ed. New York: McGraw-Hill; 2005:2255-77.
6. James CW, Sabundayo BP. Immunology of HIV infection and AIDS. In: Smith BT, ed. Concepts in immunology and immunotherapeutics. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2008:133-52.
7. Sabundayo BP, James CW. HIV treatment strategies. In: Smith BT, ed. Concepts in immunology and immunotherapeutics. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2008:153-68.
8. Hoetelmans R, van Heeswijk R, Kestens D et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation. Paper presented at Third International AIDS Society Conference of HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; 2005 Jul. Poster TuPe3.1B10.
9. Goebel F, Yakovlev A, Pozniak AL et al. Short-term antiviral activity of TMC278 - a novel NNRTI-in treatment-naive HIV-1 infected subjects. AIDS. 2006; 20:1721-6. (Pubitemid 44299363)
10. Crauwels HM, van Heeswijk R, Bollen A et al. The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI. Paper presented at the Ninth International Workshop of Pharmacology of HIV Therapy. New Orleans, LA; 2008 Apr.
11. Van Heeswijk R, Hoetelmans R, Kestens D et al. The pharmacokinetic interaction between famotidine and TMC278, a next generation NNRTI, in HIVnegative volunteers. Paper presented at the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007 Jul.
12. Crauwels HM, van Heeswijk RP, Kestens D et al. The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI. Paper presented at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9). Glasgow, United Kingdom; 2008 Nov.
13. Janssen PA, Lewi PJ, Arnold E et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzo-nitrile (R278474, rilpivirine). J Med Chem. 2005; 48:1901-9. (Pubitemid 40396320)
14. Pozniak AL, Morales-Ramirez J, Katabira E et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010; 24:55-65.
15. Molina JM, Cahn P, Grinsztejn B et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011; 378:238-46.
16. Cohen CJ, Andrade-Villanueva J, Clotet B et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-37.
17. Cohen C, Molina JM, Cahn P et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomized, phase III trials comparing TMC278 versus efavirenz in treatmentnaïve, HIV-1 infected patients. Paper presented at the XVIII International AIDS Conference. Vienna, Austria; 2010 Jul 22.
18. Van Heeswijk RP, Hoetelmans RM, Kestens D et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational NNRTI, in healthy HIV-negative volunteers. Paper presented at the 16th International AIDS Conference. Toronto, Canada; 2006 Aug.
19. McKesson. Online McKesson database. (accessed 2011 Jun 23).
20. Complera (emtricitabine-rilpivirine-tenofovir disoproxil fumarate) package insert. Foster City, CA: Gilead Sciences; 2011 Aug.
21. Aidsbeacon.com. Phase 3 clinical trial tests Truvada plus rilpivirine combination pill versus Atripla in previously untreated HIV-positive adult. www.aidsbeacon.com/tag/rilpivirine/ (accessed 2011 Jun 3).
22. Arastéh K, Rieger A, Yeni P et al. Shortterm randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther. 2009; 14:713-22.
23. Crauwels H, Vingerhoets J, Ryan R et al. Pharmacokinetic parameters of once-daily TMC278 following administration of EFV in healthy volunteers. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011 Feb 28.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. DHHS adult and adolescent antiretroviral treatment guidelines panel releases supplemental information regarding the role of rilpivirine as initial therapy. August 16, 2011. www.aidsinfo.nih.gov/ContentFiles/NNRTI-One-Page-Info-RPV.pdf (accessed 2011 Sep 1).